REN and cardiac hypertrophy: It has also been shown that CFEVs can target angiotensin II receptor type 1 (AT1R) and 2 (AT2R) and chronic activation of the myocardial renin-angiotensin system (RAS), leading to increased levels of angiotensin II (Ang II), which also contributes to cardiac hypertrophy and heart failure [184].